An independent literature search was performed on the topic 'AF in cancer patients' with the assistance of professional librarians. The search terms included anticoagulation, cancer, cardioncology, vitamin K antagonist, direct oral anticoagulants, bleeding risk and embolic risk.
AF and Cancer
AF is the most common sustained cardiac arrhythmia, with an estimated prevalence of 3% in adults aged 20 years, and higher in older people. 1 An association between AF and malignant cancer has been reported, but is incompletely defined. 2 Cancer is one of the chronic pathologies whose survival has increased in past decades. The onset of AF may be related to comorbidities, direct tumour effects, or it can be triggered by paraneoplastic conditions, left ventricular dysfunction or toxic effects of cancer treatment. It remains unclear if cancer acts as a risk factor or a marker of the arrhythmia, and the relationship between AF and cancer seems to be bidirectional. It has even been suggested that AF may act as a marker for occult cancer. 3 In surgical patients admitted with a new diagnosis of colorectal or breast cancer, AF was twice as common (3.6% versus 1.6%) compared with patients admitted for non-neoplastic surgery. 4 The highest incidence of cancer-related AF has been described in postoperative in patients undergoing lung resection. 5 In the large Women's Health Study cohort, the authors reported that the incidence of cancer was significantly higher in women with AF than in women without AF. The risk of cancer was threefold greater within 3 months of AF diagnosis and still elevated beyond 1 year. On the other hand, the risk of incident AF after diagnosis of cancer was 20% higher in the first 3 months after diagnosis of cancer, but not beyond. 6 In the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF), it was found that approximately one in four AF patients had a history of cancer. 7 Patients with both diagnoses had a higher burden of cardiovascular risk factors and concomitant cardiovascular disease.
Specific Risks of AF in Cancer Patients
Cancer is a prothrombotic state leading to increased risk of stroke. 8 Moreover, stroke in patients with cancer has been associated with worse outcomes, including prolonged hospitalisation and disability, when compared with cerebrovascular events in patients without cancer. 9 Some anticancer therapies have been associated with both thromboembolic complications and increased risk of bleeding events. 
therapeutic range was similar. 7 In this study, the risk of stroke, systemic embolism, heart failure and cardiovascular death was similar between those with and without a history of cancer, but patients with a history of cancer were at higher risk of major bleeding.
Risk Scores in Cancer Patients
A European Society of Cardiology position paper admits that the embolic-haemorrhagic risk balance can be modified in AF and cancer, and points out the lack of validation of the main risk prediction scales CHA 2 DS 2 -VASc and HAS-BLED. When proposing anticoagulant treatment for cancer patients with AF, the same recommendations are followed as in non-oncological patients, despite the lack of specific evidence. Low-molecular-weight heparins seem to have a more favourable profile in this group of patients, and potential antitumour and antimetastatic effects have been suggested in some studies, although these effects have not been confirmed. 20 There is a clear reduction in quality of life associated with long-term administration of subcutaneous drugs.
The advent of direct-acting oral anticoagulants (DOACs) -dabigatran, apixaban, rivaroxaban and edoxaban -has led to a revolution in the antithrombotic treatment of AF. In pivotal studies, a dosage of 150 mg twice daily of dabigatran reduced stroke and systemic embolism compared with warfarin, without significant differences in bleeding events, while dabigatran at a dosage of 110 mg twice daily was non-inferior to warfarin for prevention of stroke and embolism, with less bleeding. In this study, patients with a diagnosis of cancer were excluded. 21 A dosage of 5 mg twice daily of apixaban also decreased the rate of bleeding and mortality -with greater protection against strokes and embolisms -than warfarin. Patients with a life expectancy of less than a year were excluded. 22 Rivaroxaban once daily proved non-inferior to warfarin for the prevention of strokes and embolisms, with a lower incidence of intracranial bleeding.
Patients with a life expectancy of less than 2 years were excluded, so it is hard to obtain conclusions valid for cancer patients. While all of these drugs have been tested in the general population, available information in patients with cancer and AF is scarce.
Although cancer did not constitute an absolute contraindication for participation in the clinical trials, patients with a short life expectancy were excluded. As such, we do not have specific data on the safety and efficacy of DOACs in patients with AF and cancer. In the pivotal clinical trials of DOACs for patients with deep vein thrombosis, the number of patients with cancer was also small, between 2.6% and 6.0%. In addition, information on the type of cancer, the stage and the concomitant use of chemotherapy were not collected. These are retrospective analyses of the original trails, and the number of patients with cancer was too low to obtain solid conclusions. [21] [22] [23] [24] The relationship between stroke and cancer is complex. Stroke is common in cancer patients, and cancer patients with ischaemic stroke often show different risk factors, stroke biomarkers and stroke aetiology compared with non-cancer patients with ischaemic stroke. 25 There has been controversy in regard to the risk factors in the pathogenesis of stroke in cancer patients. The presence of a hypercoagulable state and increased D-dimer levels are common. 26, 27 In a subanalysis of the
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Atrial Fibrillation (ROCKET-AF), after adjusting for competing risks, the estimated Until clinical trials are conducted to verify the efficacy and usefulness of DOAC specifically in oncological patients, the clinician should rely on observational studies, as more robust evidence is not available.
Conclusion
The management of antithrombotic therapy for stroke prevention in oncologic patients with AF is challenging and it can determine their outcomes in terms of bleeding and embolic events. It requires involvement of cardiologists and oncologists to individualise the treatment for each case and offer the best therapy. Specific clinical trials are needed to assess the best treatment for these patients. Given the available data from observational studies, DOACs seem to be a safe choice for this group of patients.
